Launch of Pfizer drug to bring relief in skin disease

Pfizer, the global biopharmaceutical company, held a launch ceremony for Cibinqo – an oral, once-daily highly selective JAK1 (Janus kinase 1) inhibitor, for treating adult patients with moderate-to-severe atopic dermatitis -- in China on Sunday. [Photo/VCG]

Pfizer, the global biopharmaceutical company, held a launch ceremony for Cibinqo – an oral, once-daily highly selective JAK1 (Janus kinase 1) inhibitor, for treating adult patients with moderate-to-severe atopic dermatitis -- in China on Sunday.

Launch ceremonies for this product were held in 10 cities, including Beijing, Shanghai and Guangzhou, across China.

Jean-Christophe Pointeau, president of China Pfizer Biopharmaceutical Group, said that Cibinqo is the group's globally ground-breaking innovative product in inflammation and immunology, and a crucial part of its dermatology strategic planning in China.

The launch of this inhibitor marks a globally synchronized R&D and regulatory application process and Pfizer's second breakthrough in Atopic dermatitis (AD) treatment.

By further enriching the AD portfolio, Pfizer is set to meet the full range of treatment needs for AD patients with mild, moderate and severe atopic dermatitis.

Atopic dermatitis is a common chronic skin disease characterized by intense itching, skin inflammation and skin barrier defects.

Professor Wang Hua, director of the department of dermatology at Children's Hospital Affiliated with Chongqing Medical University, said that despite much progress in AD treatment in recent years, the lack of patient awareness about the disease often causes illness relapses and delays, while the lack of standardized treatment is increasing the burden of the disease.

The launch of this product can fulfill the urgent needs in rapid itch relief and help more moderate-to-severe AD patients alleviate suffering and return to normal work and life, said Wang.